Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress

Choong Hyun Lee, Joon Ha Park, Ki Yeon Yoo, Jung Hoon Choi, In Koo Hwang, Pan Dong Ryu, Do Hoon Kim, Young Guen Kwon, Young Myeong Kim, Moo Ho Won

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Selective serotonin re-uptake inhibitors (SSRI) have been widely used in treatment of major depression because of their efficacy, safety, and tolerability. Escitalopram, an SSRI, is known to decrease oxidative stress in chronic stress animal models. In the present study, we examined the neuroprotective effects of pre- and post-treatments with 20. mg/kg and 30. mg/kg escitalopram in the gerbil hippocampal CA1 region (CA1) after transient cerebral ischemia. Pre-treatment with escitalopram protected against ischemia-induced neuronal death in the CA1 after ischemia/reperfusion (I/R). Post-treatment with 30. mg/kg, not 20. mg/kg, escitalopram had a neuroprotective effect against ischemic damage. In addition, 20. mg/kg pre- and 30. mg/kg post-treatments with escitalopram increased brain-derived neurotrophic factor (BDNF) protein levels in the ischemic CA1 compared to vehicle-treated ischemia animals. In addition, 20. mg/kg pre- and 30. mg/kg post-treatments with escitalopram reduced microglia activation and decreased 4-hydroxy-2-nonenal and Cu,Zn-superoxide dismutase immunoreactivity and their levels in the ischemic CA1 compared to vehicle-treated ischemia animals after transient cerebral ischemia. In conclusion, these results indicated that pre- and post-treatments with escitalopram can protect against ischemia-induced neuronal death in the CA1 induced by transient cerebral ischemic damage by increase of BDNF as well as decrease of microglia activation and oxidative stress.

Original languageEnglish
Pages (from-to)450-459
Number of pages10
JournalExperimental Neurology
Volume229
Issue number2
DOIs
Publication statusPublished - 2011 Jun 1

Fingerprint

Citalopram
Brain-Derived Neurotrophic Factor
Oxidative Stress
Ischemia
Transient Ischemic Attack
Serotonin Uptake Inhibitors
Microglia
Neuroprotective Agents
Hippocampal CA1 Region
Gerbillinae
Nerve Growth Factors
Reperfusion
Animal Models
Safety

All Science Journal Classification (ASJC) codes

  • Neurology
  • Developmental Neuroscience

Cite this

Lee, Choong Hyun ; Park, Joon Ha ; Yoo, Ki Yeon ; Choi, Jung Hoon ; Hwang, In Koo ; Ryu, Pan Dong ; Kim, Do Hoon ; Kwon, Young Guen ; Kim, Young Myeong ; Won, Moo Ho. / Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress. In: Experimental Neurology. 2011 ; Vol. 229, No. 2. pp. 450-459.
@article{4a9fbe70e2be4d5093d6d7d468071b82,
title = "Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress",
abstract = "Selective serotonin re-uptake inhibitors (SSRI) have been widely used in treatment of major depression because of their efficacy, safety, and tolerability. Escitalopram, an SSRI, is known to decrease oxidative stress in chronic stress animal models. In the present study, we examined the neuroprotective effects of pre- and post-treatments with 20. mg/kg and 30. mg/kg escitalopram in the gerbil hippocampal CA1 region (CA1) after transient cerebral ischemia. Pre-treatment with escitalopram protected against ischemia-induced neuronal death in the CA1 after ischemia/reperfusion (I/R). Post-treatment with 30. mg/kg, not 20. mg/kg, escitalopram had a neuroprotective effect against ischemic damage. In addition, 20. mg/kg pre- and 30. mg/kg post-treatments with escitalopram increased brain-derived neurotrophic factor (BDNF) protein levels in the ischemic CA1 compared to vehicle-treated ischemia animals. In addition, 20. mg/kg pre- and 30. mg/kg post-treatments with escitalopram reduced microglia activation and decreased 4-hydroxy-2-nonenal and Cu,Zn-superoxide dismutase immunoreactivity and their levels in the ischemic CA1 compared to vehicle-treated ischemia animals after transient cerebral ischemia. In conclusion, these results indicated that pre- and post-treatments with escitalopram can protect against ischemia-induced neuronal death in the CA1 induced by transient cerebral ischemic damage by increase of BDNF as well as decrease of microglia activation and oxidative stress.",
author = "Lee, {Choong Hyun} and Park, {Joon Ha} and Yoo, {Ki Yeon} and Choi, {Jung Hoon} and Hwang, {In Koo} and Ryu, {Pan Dong} and Kim, {Do Hoon} and Kwon, {Young Guen} and Kim, {Young Myeong} and Won, {Moo Ho}",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.expneurol.2011.03.015",
language = "English",
volume = "229",
pages = "450--459",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress. / Lee, Choong Hyun; Park, Joon Ha; Yoo, Ki Yeon; Choi, Jung Hoon; Hwang, In Koo; Ryu, Pan Dong; Kim, Do Hoon; Kwon, Young Guen; Kim, Young Myeong; Won, Moo Ho.

In: Experimental Neurology, Vol. 229, No. 2, 01.06.2011, p. 450-459.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pre- and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress

AU - Lee, Choong Hyun

AU - Park, Joon Ha

AU - Yoo, Ki Yeon

AU - Choi, Jung Hoon

AU - Hwang, In Koo

AU - Ryu, Pan Dong

AU - Kim, Do Hoon

AU - Kwon, Young Guen

AU - Kim, Young Myeong

AU - Won, Moo Ho

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Selective serotonin re-uptake inhibitors (SSRI) have been widely used in treatment of major depression because of their efficacy, safety, and tolerability. Escitalopram, an SSRI, is known to decrease oxidative stress in chronic stress animal models. In the present study, we examined the neuroprotective effects of pre- and post-treatments with 20. mg/kg and 30. mg/kg escitalopram in the gerbil hippocampal CA1 region (CA1) after transient cerebral ischemia. Pre-treatment with escitalopram protected against ischemia-induced neuronal death in the CA1 after ischemia/reperfusion (I/R). Post-treatment with 30. mg/kg, not 20. mg/kg, escitalopram had a neuroprotective effect against ischemic damage. In addition, 20. mg/kg pre- and 30. mg/kg post-treatments with escitalopram increased brain-derived neurotrophic factor (BDNF) protein levels in the ischemic CA1 compared to vehicle-treated ischemia animals. In addition, 20. mg/kg pre- and 30. mg/kg post-treatments with escitalopram reduced microglia activation and decreased 4-hydroxy-2-nonenal and Cu,Zn-superoxide dismutase immunoreactivity and their levels in the ischemic CA1 compared to vehicle-treated ischemia animals after transient cerebral ischemia. In conclusion, these results indicated that pre- and post-treatments with escitalopram can protect against ischemia-induced neuronal death in the CA1 induced by transient cerebral ischemic damage by increase of BDNF as well as decrease of microglia activation and oxidative stress.

AB - Selective serotonin re-uptake inhibitors (SSRI) have been widely used in treatment of major depression because of their efficacy, safety, and tolerability. Escitalopram, an SSRI, is known to decrease oxidative stress in chronic stress animal models. In the present study, we examined the neuroprotective effects of pre- and post-treatments with 20. mg/kg and 30. mg/kg escitalopram in the gerbil hippocampal CA1 region (CA1) after transient cerebral ischemia. Pre-treatment with escitalopram protected against ischemia-induced neuronal death in the CA1 after ischemia/reperfusion (I/R). Post-treatment with 30. mg/kg, not 20. mg/kg, escitalopram had a neuroprotective effect against ischemic damage. In addition, 20. mg/kg pre- and 30. mg/kg post-treatments with escitalopram increased brain-derived neurotrophic factor (BDNF) protein levels in the ischemic CA1 compared to vehicle-treated ischemia animals. In addition, 20. mg/kg pre- and 30. mg/kg post-treatments with escitalopram reduced microglia activation and decreased 4-hydroxy-2-nonenal and Cu,Zn-superoxide dismutase immunoreactivity and their levels in the ischemic CA1 compared to vehicle-treated ischemia animals after transient cerebral ischemia. In conclusion, these results indicated that pre- and post-treatments with escitalopram can protect against ischemia-induced neuronal death in the CA1 induced by transient cerebral ischemic damage by increase of BDNF as well as decrease of microglia activation and oxidative stress.

UR - http://www.scopus.com/inward/record.url?scp=79956155995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956155995&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2011.03.015

DO - 10.1016/j.expneurol.2011.03.015

M3 - Article

C2 - 21458451

AN - SCOPUS:79956155995

VL - 229

SP - 450

EP - 459

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -